35 results about "Gastrin" patented technology

The application provides a culture medium and a culture method of ovarian cancer primary cells. The culture medium comprises an MST1 / 2 kinase inhibitor, sodium pyruvate, forskolin, epidermal growth factor, gastrin, fibroblast growth factor 7, nicotinamide, SB431542, and fetal bovine serum. Compared with the existing culture method, the in-vitro culture using the culture medium of the application has higher amplification efficiency; the culture of the ovarian cancer primary cells using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the ovarian cancer primary cell culture.

To provide a radionuclide complex solution of high concentration and high chemical stability which can be used as a medicine for diagnosis and / or treatment.SOLUTION: Provided is a pharmaceutical composition comprising: (a) a complex formed by: (ai) a radionuclide; and (aii) a gastrin releasing peptide receptor peptide antagonist binding moiety linked to a chelating agent; (b) at least two stabilizers against radiolysis; and (c) optionally a surfactant.SELECTED DRAWING: None

The invention provides an organoid culture medium, an organoid culture method and application of the organoid culture medium, the organoid culture medium comprises a first-stage culture medium, the first-stage culture medium comprises a first-stage basic culture medium and first-stage addition factors, and the first-stage addition factors comprise N-acetylcysteine, nicotinamide, a ROCK inhibitor, Noggin, R-spondin, EGF, HGF, Gastrin, FGF10, Blebbistatin, Forskolin, A83-01, LDN193189, DAPT, TGF-alpha and UDAC. By using the organoid culture medium, the liver organoid and the fatty liver organoid can be effectively obtained, and the obtained fatty liver organoid has obvious fat deposition, is sensitive to fatty liver treatment drugs, highly restores the physiological status when human body fatty liver diseases occur, and has high application value.

There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.

The present application belongs to the technical field of protein short peptide, and discloses a gastrin releasing peptide precursor specific binding short peptide and application. The gastrin releasing peptide precursor is a tumor marker with high specificity and sensitivity, and plays an important role in early diagnosis, curative effect monitoring and prognosis judgment of non-small cell lung cancer. The present application obtains a gastrin releasing peptide precursor short peptide P2 through phage display technology, and the amino acid sequence is shown as SEQ ID NO. 1. The specific short peptide screened by the present application has the characteristics of small relative molecular mass and high affinity, and thus a probe can be designed for detecting the gastrin releasing peptide precursor, thereby providing a new direction for early diagnosis of tumors and research and development of targeted drugs in clinic.

The present invention relates to the field of probiotics, in particular to an Akkermansia muciniphila MG784 for alleviating constipation, promoting defecation, improving intestinal barrier function and intestinal immunity, and its uses. The Akkermansia muciniphila MG784 provided by the present invention has the deposition number DSM 35549. The Akkermansia muciniphila MG784 provided by the present invention can increase the levels of motilin (MTL), gastrin (GAS), and acetylcholine in the gastrointestinal tract, promote intestinal peristalsis, improve the small intestine propulsion rate, and ameliorate defecation time and fecal output. Furthermore, Akkermansia muciniphila MG784 can also alleviate colonic mucosal inflammation, improve the thickness of the digestive tract muscular layer, modulate the structure of the intestinal microbiota, significantly increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria.

The application provides a culture medium and a culture method of a gastric cancer organoid. The culture medium comprises an MST1 / 2 kinase inhibitor, a fibroblast growth factor 7, R-spondin 1, hydrocortisone, a B27 supplement, an N2 supplement, insulin, a dual regulatory protein, at least one Rho protein kinase inhibitor selected from Y27632, fasudil and H-1152, forskolin, gastrin, fetal bovine serum and cholera toxin. Compared with the existing culture method, the in-vitro culture using the culture medium has higher amplification efficiency; the culture of the gastric cancer organoid using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the gastric cancer organoid culture.

A composition contains (i) rapamycin and / or a rapalog and (ii) a radiolabeled gastrin analogue. The composition can be used for the treatment and / or diagnosis of CCKB receptor positive cancer or tumors and leads to superior tumor uptake of radiolabeled gastrin analogue, resulting in improved delivery and therapeutic efficacy while cytotoxic side-effects are prevented and / or reduced.

The utility model discloses a kind of mixing equipment of gastrin 17 detection reagent, including mixing shell, the top wall of the mixing shell is provided with feed pipe, further including mixing mechanism;Mixing mechanism: it includes driving shaft, connecting rod, outer stirrer, pivot, inner stirrer and transmission assembly, the mixing equipment of this gastrin 17 detection reagent, multiple operation is driven by primary, by outer stirring component rotation around device vertical axis, to mix uniform stirring to the mixing equipment raw material of gastrin 17 detection reagent at the edge of device internal wall body, by inner stirring component rotation around device horizontal horizontal axis, to mix uniform stirring to the mixing equipment raw material of gastrin 17 detection reagent at the central part of device inside, while the mixing equipment raw material of gastrin 17 detection reagent between two groups of stirring components is mutually crossed collision mixing, effectively improve the mixing efficiency of device to the mixing equipment raw material of gastrin 17 detection reagent.

The application discloses a culture medium for constructing a gastric cancer ovary metastasis microtumor model and application. The application relates to the technical field of biotechnology, and provides a culture medium for constructing a gastric cancer ovary metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant protein EGF, bFGF, HGF, FGF-10, Wnt-3a, Noggin, R-spondin 1, Follistatin, CHIR99021, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additives, cholera toxin, B27, ITS-X, Y-27632, gastrin, prostaglandin E2, beta-estradiol, progesterone, Galunisertib and a basic culture medium. The culture success rate of the gastric cancer ovary metastasis microtumor model is effectively improved.

The present application relates to the technical field of electrochemiluminescence immunoassay, and discloses a preparation for detecting progastrin-releasing peptide and application thereof, which contains a phosphate buffer, an alkali metal inorganic salt, bovine serum albumin, a preservative, a first surfactant and a second surfactant. The preparation has good universality and can be used for the preparation of monoclonal antibody coated magnetic microspheres and a working solution of a ruthenium compound labeled monoclonal antibody. The preparation can not only enhance the luminescence signal intensity of the reagent, but also ensure the stable performance of the reagent during long-term storage, thereby effectively enhancing the clinical applicability of the detection system and the reliability of the detection result.

The present invention relates to gastrin-releasing peptide receptor (GRPR)-targeted compounds and their use for imaging and treatment of diseases or conditions characterized by expression of the gastrin-releasing peptide receptor.

Provided are methods for preventing initiation and / or progression of gastrin-associated tumors and / or cancers in subjects. In some embodiments, the methods relate to administering compositions that gastrin immunogens to subjects. Also provided are methods for inhibiting development of gastrin-associated precancerous lesions, methods for preventing formation of fibrosis associated with a tumor and / or a cancer, uses of compositions that include a gastrin immunogen to prevent initiation and / or development of a gastrin-associated tumor or cancer and / or for preparing medicaments therefor, and compositions for use in preventing initiation and / or development of gastrin-associated tumors and / or cancers and / or precancerous lesions thereof.

The invention provides a multisystem disease analysis method based on gastrin plasma proteomics, which comprises the following steps of: A, analyzing a large number of adult individuals subjected to baseline evaluation by using queue research data of a biological sample library, and measuring a plurality of plasma proteins; b, analyzing a standardized protein expression (NPX) value of gastrin (GAST) by adopting a multivariable Cox proportional risk model, and correcting by using Bonferroni so as to reduce a false positive result; and C, exploring the correlation between the GAST-PRS and the disease phenotype by adopting full phenotype correlation analysis (PheWAS) based on polygene risk score (PRS), and further analyzing the genetic correlation between the GAST and the disease by using linkage imbalance score regression (LDSC). According to the method, the GAST can be redefined as a cross-system risk regulation factor, and the method is of great significance to layering of patients with shared pathway imbalance. The GAST has multi-system correlation with morbidity and mortality in the outcome of 168 diseases, and challenges the classical normal form of the gastrointestinal specific function of the GAST. These findings establish the location of GAST as a multi-system risk indicator.

The present invention relates to gastrin-releasing peptide receptor (GRPR)-targeted compounds and their use for imaging and treatment of diseases or conditions characterized by expression of the gastrin-releasing peptide receptor.

The invention discloses a composition for constructing an IOPN organ model, a model construction method and application. The composition for constructing the IOPN organoid model comprises an organoid model culture medium, and the organoid model culture medium comprises a penicillin-streptomycin double antibody solution, GlutaMAX, a serum-free supplement, Rspo-1, a Wnt activator, a growth factor, an HEPES buffer solution, N-acetyl-L-cysteine, a gastrin hormone, nicotinamide, forskolin, an ALK inhibitor, a ROCK inhibitor and the balance of a basic culture medium. The IOPN type organ model cultured by the composition for constructing the IOPN type organ model can maintain the original characteristics of tumors, provides a reliable biological model for pathological research and drug research and development of pancreatic tumors, and is convenient to operate and low in cost.

The invention discloses an amino acid and enzyme preparation nutrient mixture for promoting proliferation of gastrointestinal cells of dogs, and belongs to the technical field of pet food. According to the invention, the proliferation of intestinal epithelial cells and the secretion of Gastrin can be effectively promoted by supplementing arginine. In order to enhance the functional effect of the invention, lactase is especially added in the invention. On the basis of normal diet, 0.125%-0.5% of arginine and 0.00375%-0.015% of lactase are complementarily fed every day. The digestion and absorption of the dogs on nutrient substances of staple food grains can be improved, the parasitic quantity of intestinal escherichia coli of the dogs can be reduced, and excrement in a healthy form can be formed. In addition, the nutritional mixture can significantly promote the expression of epidermal growth factors (EGF). The invention discloses a mechanism for promoting proliferation of canine intestinal epithelial cells by arginine and lactase, and provides a new thought for prevention and treatment of canine digestive diseases.

Described herein are gastrin releasing peptide receptor (GRPR) binding peptide ligands having the formula: R1-R2-R3-(Q)-Z; wherein R1 is absent or is a chelator moiety, optionally chelated to a radioactive atom moiety; R2 is absent or is a linker; R3 is selected from the group consisting of an amino acid sequence having between 1-5 amino acids, or is absent; "Q" is a cyclic peptide sequence having between 4-7 amino acids; "Z" is a linear peptide sequence having between 4- 8 amino acids. Described herein are exemplary GRPR-binding peptide ligands and methods for diagnosis and treatment using them, in particular in relation to various types of cancer associated with GRPR expression.

The present invention relates generally to the identification and / or treatment of cancer, particularly cancers in which the gastrin-releasing peptide receptor (GRPR) is expressed. In particular embodiments, the present invention relates to the identification and / or treatment of prostate cancer, particularly GRPR-expressing metastatic castration-resistant prostate cancer.

This invention discloses the application of Amomum villosum extract in the preparation of drugs for the prevention and treatment of functional dyspepsia, belonging to the field of biotechnology. The extract, when applied to the prevention and / or treatment of functional dyspepsia, can increase plasma levels of motilin (MTL) and gastrin (GAS), promote gastrointestinal motility, significantly improve gastric emptying rate in functional dyspepsia model mice, improve pathological damage to gastric tissue, restore mitochondrial function in gastric tissue, and regulate the expression of related factors in gastric tissue. Even at low doses, it can effectively increase plasma MTL and GAS levels in loperamide hydrochloride-induced functional dyspepsia model mice, improve gastric emptying rate, effectively improve pathological damage to gastric tissue in these mice, and regulate the expression of related factors in the gastric tissue. The raw materials of this invention are derived from natural products, are easy to collect, and have high safety.

Provided herein are peptide analogs of gastrin releasing peptide (GRP), corresponding pharmaceutical compositions, and methods of using such peptide analogs of GRP in the treatment of a disease or disorder, such as gastrointestinal disease or obesity.

This invention relates to compositions and methods for detecting and treating esophageal cancer, including methods for in vitro diagnosis of esophageal cancer, and to compositions and methods for preventing or treating esophageal cancer, wherein the compositions comprise antibodies that bind progastrin and the methods comprise using antibodies that bind progastrin.

The invention relates to the field of biological detection, in particular to a polypeptide and application thereof in preparation of a product for detecting gastrin 17. The invention provides a polypeptide which has an amino acid sequence as shown in SEQ ID NO: 1. The invention provides a method for effectively improving the stability of the gastrin 17 polypeptide, the gastrin 17 polypeptide is stored in a non-serum matrix at 37 DEG C for 10 days or stored in a serum matrix at 2-8 DEG C for 7 days, the titer reduction amplitude does not exceed 10%, and the stability of the gastrin 17 polypeptide serving as a calibration product and a quality control product is greatly improved.

The invention relates to a bile duct cancer organoid culture medium and application thereof, and belongs to the technical field of biomedicine. The bile duct cancer organ culture medium provided by the invention is prepared from the following components: a TGF (Transforming Growth Factor)-beta signal channel inhibitor A83-01, an epidermal growth factor (EGF), a fibroblast growth factor FGF10, a hepatocyte growth factor HGF, an adenylate cyclase activator Forskolin, a gastrin analogue Gastrin I, nicotinamide Nicotinamide, a ROCK kinase inhibitor Y-27632, glucocorticoid dexamethasone, a compound antibiotic, a cell factor oncostatin M and FGF-23. The culture medium disclosed by the invention is reasonable in formula design, all the components have a synergistic effect, long-term stable amplification of bile duct cancer organs can be effectively maintained, and a good cryopreservation resuscitation characteristic is maintained. A liver cancer organ model established on the basis of the culture medium provides a reliable experimental platform for exploring pathogenesis of bile duct cancer and developing related drug research and development.

The invention provides an isotope dilution mass spectrometry valuing method for a plasma gastrin-releasing peptide precursor. According to the method, two plasma pretreatment strategies of immunoaffinity capture and protein precipitation are adopted, and an isotope dilution mass spectrometry technology is combined, so that high-accuracy quantification of the ProGRP in the plasma is realized. Target protein is efficiently enriched through two complementary pretreatment methods respectively, after trypsin digestion, isotope-labeled characteristic peptide fragments are introduced to serve as internal labels, absolute quantification is conducted on ProGRP through isotope dilution mass spectrometry, and the measurement result is traceable to the international unit (SI). The method effectively overcomes measurement deviation caused by cross reaction in a traditional immunoassay method, has high recovery rate, high specificity and high sensitivity, is suitable for reliable and accurate value determination of ProGRP in plasma, and can be used as a candidate scheme of a protein reference measurement procedure.

The present invention relates to methods for the in vitro diagnosis of gastric cancer, and to compositions and methods for the prevention or the treatment of gastric cancer. Disclosed are compositions that include an antibody binding to progastrin and disclosed are methods that include the use of an antibody binding to progastrin.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of gastritis. The composition comprises the following ingredients: Astragalus membranaceus, ginseng, Atractylodes macrocephala, fermented Cordyceps militaris powder, Lycium barbarum, Hedyotis diffusa, Fagopyrum dibotrys, Bistorta officinalis, Panax notoginseng, and Caesalpinia sappan. This invention is the first to discover and confirm that this traditional Chinese medicine composition can be used to prevent or treat chronic gastritis, especially chronic atrophic gastritis. Experiments have verified that it can significantly prevent or improve the pathological state of the gastric mucosa in rats with chronic atrophic gastritis. Specifically, it can significantly increase the serum pepsinogen I / II ratio, decrease gastrin-17 levels, reverse gastric gland atrophy, and repair the morphological structure of the gastric mucosa, achieving a systematic repair of the function and structure of the CAG gastric mucosa. Furthermore, the ingredients in this traditional Chinese medicine composition are rationally combined, and no obvious toxic side effects were observed under experimental conditions, demonstrating good safety and potential for long-term use.

To provide an improved radiotherapeutic agent for treating a disease associated with abnormal expression of a gastrin-releasing peptide receptor.SOLUTION: Provided is a bombesin-derived compound of formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-ψ-Xaa4-NH2). RX includes a radionuclide chelator or trifluoroborate-containing prosthetic group. L is a linker. Xaa1 is D-Phe or the like, and Xaa2 is Gly or the like. Xaa3 is Leu or the like, and Xaa4 is Pro or the like. A symbol ψ denotes reduced peptide bond between Xaa3 and Xaa4. In the case where Xaa4 is Pro or the like, ψ is CH2-N, or in the case where Xaa4 is Phe or Nle, ψ is CH2 N(R). R is H or a C1-C5 linear or branched alkyl. Use of the compound as a contrast medium or therapeutic agent is also provided.SELECTED DRAWING: None

The invention features dosing regimens and combination therapies utilizing radiolabeled gastrin analogues for the treatment of CCKB receptor positive diseases, including CCK2R-positive cancers and cancers at all stages of cancer spread.

The invention relates to the technical field of immunodetection, in particular to latex microspheres for detecting gastrin 17 as well as a preparation method and application of the latex microspheres. The dosage of the antibody of the gastrin 17 is reduced, so that the antibody positioning is assisted, the multi-layer coating of the latex microspheres is weakened, and the detection sensitivity of the low-value gastrin 17 is improved. According to the present invention, the gastrin 17 detection reagent is provided, the high ion reaction environment with strong buffer ability is used in the detection reagent, and the low value gastrin 17 is detected by optimizing the type and the ratio of the surface activity and cooperating with the latex microspheres of the low-concentration antibody so as to further reduce the false positive, such that the G17 detection on the biochemical analyzer has realizability, and the detection result is significant. The detection accuracy is basically equivalent to that of a magnetic particle light-emitting platform.